Australian medical device company OncoSil Medical (ASX:OSL) has achieved a new milestone in its international expansion, announcing the first patient treatment in Portugal using its innovative OncoSil device for locally advanced pancreatic cancer.
The procedure was successfully performed on 2 October 2025 at the Instituto Português de Oncologia do Porto (IPO Porto), one of Europe’s leading comprehensive cancer centres. The treatment marks the commencement of OncoSil’s commercial activities in Portugal and reinforces its growing footprint across Europe.
“We are delighted to see the first OncoSil treatment take place in Portugal, and it is particularly pleasing that this milestone was achieved at IPO Porto, a highly regarded oncology centre,” said Nigel Lange, Chief Executive Officer and Managing Director of OncoSil Medical. “The treatment represents another important deliverable in our ongoing efforts to expand patient access to OncoSil Medical’s innovative treatment across the large and growing European market.”
OncoSil’s device delivers targeted intratumoral radiation therapy using Phosphorus-32 (32P) microparticles, enabling clinicians to administer higher doses of radiation directly into pancreatic tumours while sparing surrounding healthy tissue. This approach is designed to improve outcomes for patients with unresectable locally advanced pancreatic cancer, a disease that remains one of the most lethal globally, with more than 500,000 new cases diagnosed each year and limited treatment options.
The OncoSil device holds CE Marking approval and is designated as a breakthrough device in both the European Union and the United States. It is currently approved for sale in over 30 countries, including the UK, Turkey, and Israel, with commercial treatments already undertaken in Spain, Italy, Austria, Greece, Turkey and Israel.
OncoSil Medical announced that it will continue to collaborate closely with clinicians and health authorities in Portugal to support the adoption of its technology, while also exploring new markets to expand its global presence further.